Amgen (AMGN) Net Margin Growth (3y) (2012 - 2026)

Amgen (AMGN) Net Margin Growth (3y) (2012 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin Growth (3y) (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 1,803.00
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 1,973.00
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 544.00
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 30,838.00
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn -4,534.00
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn -2,543.00
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 1,355.00
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn -58.00
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn -323.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -2,543.00
Dec 31, 2025 -33,856.00
Sep 30, 2025 143.00
Jun 30, 2025 -437.00
Mar 31, 2025 -243.00
Dec 31, 2024 -2,084.00
Sep 30, 2024 519.00
Jun 30, 2024 178.00
Mar 31, 2024 -2,941.00
Dec 31, 2023 -1,614.00
Sep 30, 2023 -640.00
Jun 30, 2023 -931.00
Mar 31, 2023 1,691.00
Dec 31, 2022 32,311.00
Sep 30, 2022 -381.00
Jun 30, 2022 -1,912.00
Mar 31, 2022 -1,402.00
Dec 31, 2021 -439.00
Sep 30, 2021 -564.00
Jun 30, 2021 -3,332.00